Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes

Pathology International

Volumn 55, Issue 10, 2005, Pages 619-625

  Jian, Zhang ^a   Tomizawa, Yoshio ^a   Yanagitani, Noriko ^b   Iijima, Hironobu ^a   Sano, Takaaki ^a   Nakajima, Takashi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b National Nishigunma Hospital   (Japan)

Author keywords

Bronchioloalveolar carcinoma; Histology; Immunohistochemistry; LOH analysis; Lung; Papillary adenocarcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 3P; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ALVEOLUS WALL; LUNG PARENCHYMA; MALE; MICROSATELLITE MARKER; MORPHOLOGY; PRIORITY JOURNAL; STAINING;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADENOCARCINOMA, PAPILLARY; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 3; DNA, NEOPLASM; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 28444446704     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01879.x     Document Type: Article

References (30)

1. Travis W, Colby T, Corrin B, Shimosato Y. World Health Organization International Histological Typing of Tumors. Histological Typing of Lung and Pleural Tumours, 3rd edn. Berlin: Springer 1999.
2. Rena O, Papalia E, Ruffini E et al. Stage I pure bronchioloalveolar carcinoma: Recurrences, survival and comparison with adenocarcinoma of the lung. Eur J Cardiothorac Surg 2003;23:409-14.
3. Noguchi M, Morikawa A, Kawasaki M et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-52.
4. Silver SA, Askin FB. True papillary carcinoma of the lung. A distinct clinicopathologic entity. Am J Surg Pathol 1997;21:43-51.
5. Aida S, Shimazaki H, Sato K et al. Prognostic analysis of pulmonary adenocarcinoma subclassification with special consideration of papillary and bronchioloalveolar types. Histopathology 2004;45:468-76.
6. Amin MB, Tamboli O, Merchant SH et al. Micropapillary component in lung adenocarcinoma: A distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002; 26:358-64.
7. Miyoshi T, Sato Y, Okumura S et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003;27:101-9.
8. Kim YH, Ishii G, Goto K et al. Dominant papillary subtype is a significant predictor of the response to Gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004;10:7311-17.
9. Sorensen JB, Hirsch FR, Olsen J. The prognostic implication of histopathological subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consequtive patients with advanced disease. Cancer 1988;62:361-7.
10. Iijima H, Tomizawa Y, Dobashi K, Saito R, Nakajima T, Mori M. Alleric loss on chromosome 3p associates with the histological features of lung adenocarcinoma. Br J Cancer 2004;91:1143-8.
11. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinoma. Am J Surg Pathol 2002;26:767-73.
12. Mizutani Y, Nakajima T, Morinaga S et al. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. Special reference to nonmucous producing lung adenocarcinoma. Cancer 1988;61:532-7.
13. Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: A study of 109 cases. Virchows Arch 2002; 440:353-61.
14. Hirano T, Auer G, Maeda M et al. Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. Jpn J Cancer Res 2000;91:1015-21.
15. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003;88:1229-33.
16. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Proganostic significance of thyroid transcription factor-1 expression in both early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol 2004; 35:3-7.
17. Tan D, Li Q, Ramnath N et al. Thyroid transcription factor-1 expression prevalence and clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003;34:597-604.
18. Laack E, Nikbakht H, Paters A et al. Expression of CEACAM1 in adenocarcinoma of the lung: A factor of independent prognostic significance. J Clin Oncol 2002;20:4279-84.
19. Sienel W, Dango S, Woelfle U et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 2003;9:2260-66.
20. Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara N. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 2001;92:446-51.
21. Iwaski T, Nakashima M, Watanabe T et al. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 2000;89:488-93.
22. Oizumi S, Yamazaki K, Nakashima M et al. RCAS1 expression: A potential prognostic marker for adenocarcinomas of the lung. Oncology 2002;62:333-9.
23. Tanaka R, Wang D, Morishita Y et al. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 2005;103:608-15.
24. Awaya H, Takeshima Y, Amatya VJ et al. Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung. Pathol Int 2004;54:486-9.
25. Kratzke RA, Greatens TM, Rubins JB et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996;56:3415-20.
26. Kawabuchi B, Moriyama S, Hironaka M et al. p16 inactivation in small-sized lung adenocarcinoma: Its association with poor prognosis, Int J Cancer 1999;84:49-53.
27. Xue Q, Sano T, Kashiwabara K, Saito M, Oyama T, Nakajima T. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. Pathol Int 2002; 52:103-9.
28. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002; 21: 6915-35.
29. Yokoyama S, Yamanaka K, Tsuchiya E, Murata M, Sakiyama S, Nakamura Y. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 1992;52:873-7.
30. Yatabe Y, Konishi H, Mitsudomi T, Nakamura S, Takahashi T. Topographical distributions of allelic loss in individual non-small-cell lung cancers. Am J Pathol 2000;157:985-93.